Similar articles for PMID: 27904868

Year	Number of Results
1881	1
2008	1
2009	1
2010	2
2011	1
2012	4
2013	9
2014	11
2015	17
2016	24
2017	25
2018	22
2019	19
2020	29
2021	32
2022	29
2023	18
2024	0

1

Predictive Ability of ¹⁸F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography for Pathological Complete Response and Prognosis after Neoadjuvant Chemotherapy in Triple-negative Breast Cancer Patients.

Kiyoto S, Sugawara Y, Hosokawa K, Nishimura R, Yamashita N, Ohsumi S, Mochizuki T. Kiyoto S, et al. Asia Ocean J Nucl Med Biol. 2016 Winter;4(1):3-11. doi: 10.7508/aojnmb.2016.04.002. Asia Ocean J Nucl Med Biol. 2016. PMID: 27904868 Free PMC article.

2

Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.

Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P, de Roquancourt A, de Cremoux P, Marty M, Hatt M, Espié M. Groheux D, et al. Eur J Cancer. 2014 Jul;50(11):1864-71. doi: 10.1016/j.ejca.2014.04.020. Epub 2014 May 16. Eur J Cancer. 2014. PMID: 24841218

3

Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.

Groheux D, Biard L, Lehmann-Che J, Teixeira L, Bouhidel FA, Poirot B, Bertheau P, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, de Cremoux P. Groheux D, et al. Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1279-1288. doi: 10.1007/s00259-018-3998-z. Epub 2018 Apr 4. Eur J Nucl Med Mol Imaging. 2018. PMID: 29616304

4

The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.

Luo J, Zhou Z, Yang Z, Chen X, Cheng J, Shao Z, Guo X, Tuan J, Fu X, Yu X. Luo J, et al. Medicine (Baltimore). 2016 Feb;95(8):e2914. doi: 10.1097/MD.0000000000002914. Medicine (Baltimore). 2016. PMID: 26937935 Free PMC article.

5

Role of ¹⁸F-PET/CT in Predicting Prognosis of Patients With Breast Cancer After Neoadjuvant Chemotherapy.

Akimoto E, Kadoya T, Kajitani K, Emi A, Shigematsu H, Ohara M, Masumoto N, Okada M. Akimoto E, et al. Clin Breast Cancer. 2018 Feb;18(1):45-52. doi: 10.1016/j.clbc.2017.09.006. Epub 2017 Sep 19. Clin Breast Cancer. 2018. PMID: 28993056

6

FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.

Buchbender C, Kuemmel S, Hoffmann O, Stahl AR, Kimmig R, Otterbach F, Ladd S, Koeninger A, Forsting M, Bockisch A, Antoch G, Heusner TA. Buchbender C, et al. Acta Radiol. 2012 Jul;53(6):628-36. doi: 10.1258/ar.2012.110699. Epub 2012 Jul 3. Acta Radiol. 2012. PMID: 22761341

7

The Value of ¹⁸F-FDG PET/CT Imaging in the Evaluation of Interim Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer.

Tatar G, Özkul Ö, Alçin G. Tatar G, et al. Mol Imaging Radionucl Ther. 2022 Jun 27;31(2):123-129. doi: 10.4274/mirt.galenos.2022.44154. Mol Imaging Radionucl Ther. 2022. PMID: 35770978 Free PMC article.

8

Complete Metabolic Response on Interim ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC. Chen S, et al. Oncologist. 2017 May;22(5):526-534. doi: 10.1634/theoncologist.2016-0334. Epub 2017 Apr 4. Oncologist. 2017. PMID: 28377466 Free PMC article.

9

Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Humbert O, Riedinger JM, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V, Kanoun S, Coutant C, Fumoleau P, Cochet A, Brunotte F. Humbert O, et al. Clin Cancer Res. 2015 Dec 15;21(24):5460-8. doi: 10.1158/1078-0432.CCR-15-0384. Epub 2015 Jun 30. Clin Cancer Res. 2015. PMID: 26130460

10

The role of basal metabolic and volumetric ¹⁸F-FDG PET/CT parameters and their changes in predicting pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy.

Kepenek F, Karaoğlan H, Can C, Kömek H, Kaplan İ, Etem H, Ebinç S, Kavak Ş, Gündoğan C. Kepenek F, et al. Hell J Nucl Med. 2022 Sep-Dec;25(3):235-246. doi: 10.1967/s002449912511. Epub 2022 Dec 14. Hell J Nucl Med. 2022. PMID: 36507879 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

221 results

Results by year